Literature DB >> 1726490

Identification and androgen-regulated expression of two major human glandular kallikrein-1 (hGK-1) mRNA species.

P H Riegman1, R J Vlietstra, H A van der Korput, J C Romijn, J Trapman.   

Abstract

The screening of an oligo(dT)-primed prostate cDNA library with a human glandular kallikrein-1 (hGK-1) genomic DNA fragment resulted in the isolation of two different hGK-1 cDNAs. A 1.2 kb cDNA (pGK-1) contains an open reading frame of 510 bp, encoding the major part of the previously predicted hGK-1 protein (Schedlich et al. (1987) DNA 6, 429-437). This cDNA contains a 3'-untranslated region of 677 nucleotides and terminates in a poly(A) stretch, preceded by the canonical AATAAA polyadenylation signal. A second cDNA (pGK-10A), with a size of 1.5 kb, contains an open reading frame of 669 nucleotides preceded by 16 nucleotides of the 5'-untranslated region. pGK-10A differs from pGK-1 by the presence of an additional 37 bp fragment, interrupting the protein coding region of hGK-1, which results from the use of an alternative splice donor site of intron IV of the hGK-1 gene. The mature protein (excluding presumed pre- and propeptides) as deduced from the pGK-10A cDNA sequence, has a size of 199 amino acids and differs at the COOH-terminus from the 237 amino acid hGK-1 protein. The alternatively spliced mRNA comprises approximately 20% of the hGK-1 transcripts, as deduced from analysis of mRNA from prostate cells by PCR amplification of specific fragments. The regulation of hGK-1 mRNA expression was studied in different human prostate tumors and cell lines by Northern blotting, using a hGK-1-specific oligonucleotide probe. A high level of hGK-1 expression was found in the androgen-dependent tumors PC 82 and PC EW. hGK-1 mRNA was also present in the androgen-sensitive LNCaP cell line, but undetectable in the androgen-insensitive prostate tumors PC 133, PC 135 and the PC 3 cell line. In LNCaP cells, the expression of hGK-1 mRNA was strongly induced by androgens. Regulation of expression of the closely related prostate-specific antigen (PA) gene showed a similar pattern.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1726490     DOI: 10.1016/0303-7207(91)90272-t

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  10 in total

1.  Peripheral blood rt-PCR assays for detection and prognosis of prostate cancer.

Authors:  Shahrokh F Shariat; Kevin M Slawin
Journal:  Rev Urol       Date:  2003

2.  Immunohistochemical study suggesting a complementary role of kallikreins hK2 and hK3 (prostate-specific antigen) in the functional analysis of human prostate tumors.

Authors:  R R Tremblay; D Deperthes; B Têtu; J Y Dubé
Journal:  Am J Pathol       Date:  1997-02       Impact factor: 4.307

3.  A novel protease homolog differentially expressed in breast and ovarian cancer.

Authors:  A Anisowicz; G Sotiropoulou; G Stenman; S C Mok; R Sager
Journal:  Mol Med       Date:  1996-09       Impact factor: 6.354

4.  Identification of tissue kallikrein messenger RNA in human neutrophils.

Authors:  H F Wu; R D Venezie; W M Cohen; J W Jenzano; G L Featherstone; R L Lundblad
Journal:  Agents Actions       Date:  1993-01

5.  Development of seven new human prostate tumor xenograft models and their histopathological characterization.

Authors:  W M van Weerden; C M de Ridder; C L Verdaasdonk; J C Romijn; T H van der Kwast; F H Schröder; G J van Steenbrugge
Journal:  Am J Pathol       Date:  1996-09       Impact factor: 4.307

6.  Simultaneous quantification of human glandular kallikrein 2 and prostate-specific antigen mRNAs in peripheral blood from prostate cancer patients.

Authors:  A Ylikoski; M Karp; K Pettersson; H Lilja; T Lövgren
Journal:  J Mol Diagn       Date:  2001-08       Impact factor: 5.568

Review 7.  Androgen receptor gene mutations in prostate cancer. Implications for disease progression and therapy.

Authors:  Z Culig; A Hobisch; A Hittmair; M V Cronauer; C Radmayr; G Bartsch; H Klocker
Journal:  Drugs Aging       Date:  1997-01       Impact factor: 3.923

8.  EPA Modulates KLK Genes via miR-378: A Potential Therapy in Prostate Cancer.

Authors:  Kai-Jie Yu; De-Yi Ji; Ming-Li Hsieh; Cheng-Keng Chuang; See-Tong Pang; Wen-Hui Weng
Journal:  Cancers (Basel)       Date:  2022-06-06       Impact factor: 6.575

9.  Tissue specific and androgen-regulated expression of human prostate-specific transglutaminase.

Authors:  H J Dubbink; N S Verkaik; P W Faber; J Trapman; F H Schröder; J C Romijn
Journal:  Biochem J       Date:  1996-05-01       Impact factor: 3.857

10.  The promoter and the enhancer region of the KLK 3 (prostate specific antigen) gene is frequently mutated in breast tumours and in breast carcinoma cell lines.

Authors:  S Majumdar; E P Diamandis
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.